Comments

NextCure

NXTCNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$1.74
-0.04-2.25%
Last update: 11:20 AM
15 minutes delayed
NextCure (NXTC) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$15.00
Lowest Price Target1
$4.00
Consensus Price Target1
$8.25

want to know what
the Bulls & Bears Say?

NextCure (NASDAQ:NXTC) Stock, Analyst Ratings, Price Targets, Forecasts

NextCure Inc has a consensus price target of $8.25 based on the ratings of 5 analysts. The high is $15 issued by Truist Securities on August 23, 2022. The low is $4 issued by Needham on May 3, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 3, 2024, May 31, 2024, and May 3, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 365.12% upside for NextCure Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Needham
Piper Sandler
Truist Securities

1calculated from analyst ratings

Analyst Ratings for NextCure

Buy NowGet Alert
06/03/2024Buy Now365.12%HC Wainwright & Co.
Emily Bodnar
$8 → $8ReiteratesBuy → BuyGet Alert
05/31/2024Buy Now365.12%HC Wainwright & Co.
Emily Bodnar
$8 → $8ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now365.12%HC Wainwright & Co.
Emily Bodnar
 → $8ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now132.56%Needham
Gil Blum
 → $4ReiteratesBuy → BuyGet Alert
03/22/2024Buy Now365.12%HC Wainwright & Co.
Emily Bodnar
$5 → $8MaintainsBuyGet Alert
03/20/2024Buy Now132.56%Needham
Gil Blum
$4 → $4MaintainsBuyGet Alert
12/14/2023Buy Now132.56%Needham
Gil Blum
$6 → $4MaintainsBuyGet Alert
08/08/2023Buy Now306.98%HC Wainwright & Co.
Emily Bodnar
 → $7Initiates → BuyGet Alert
08/04/2023Buy Now248.84%Needham
Gil Blum
 → $6ReiteratesBuy → BuyGet Alert
05/05/2023Buy Now248.84%Needham
Gil Blum
 → $6Reiterates → BuyGet Alert
03/03/2023Buy Now248.84%Needham
Gil Blum
 → $6Reiterates → BuyGet Alert
11/04/2022Buy Now—Ladenburg Thalmann
Aydin Huseynov
—DowngradeBuy → NeutralGet Alert
11/04/2022Buy Now248.84%Needham
Gil Blum
$12 → $6MaintainsBuyGet Alert
11/04/2022Buy Now248.84%Piper Sandler
Edward Tenthoff
$13 → $6MaintainsOverweightGet Alert
08/23/2022Buy Now772.09%Truist Securities
Asthika Goonewardene
$19 → $15MaintainsBuyGet Alert
05/23/2022Buy Now655.81%Piper Sandler
Edward Tenthoff
$21 → $13MaintainsOverweightGet Alert
03/01/2022Buy Now830.23%Ladenburg Thalmann
Aydin Huseynov
 → $16Initiates → BuyGet Alert
11/05/2021Buy Now713.95%Needham
Gil Blum
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for NextCure (NXTC) stock?

A

The latest price target for NextCure (NASDAQ:NXTC) was reported by HC Wainwright & Co. on June 3, 2024. The analyst firm set a price target for $8.00 expecting NXTC to rise to within 12 months (a possible 359.77% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for NextCure (NXTC)?

A

The latest analyst rating for NextCure (NASDAQ:NXTC) was provided by HC Wainwright & Co., and NextCure reiterated their buy rating.

Q

When was the last upgrade for NextCure (NXTC)?

A

There is no last upgrade for NextCure

Q

When was the last downgrade for NextCure (NXTC)?

A

The last downgrade for NextCure Inc happened on November 4, 2022 when Ladenburg Thalmann changed their price target from N/A to N/A for NextCure Inc.

Q

When is the next analyst rating going to be posted or updated for NextCure (NXTC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.

Q

Is the Analyst Rating NextCure (NXTC) correct?

A

While ratings are subjective and will change, the latest NextCure (NXTC) rating was a reiterated with a price target of $8.00 to $8.00. The current price NextCure (NXTC) is trading at is $1.74, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch